Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients

被引:14
|
作者
Lindqvist, Jonatan [1 ,2 ]
Jekunen, Antti [2 ,3 ]
Sihvo, Eero [4 ]
Johansson, Mikael [1 ]
Andersen, Heidi [2 ,5 ]
机构
[1] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden
[2] Vaasa Cent Hosp, Canc Clin, Vaasa, Finland
[3] Turku Univ, Oncol Dept, Turku, Finland
[4] Cent Hosp Cent Finland, Jyvaskyla, Finland
[5] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
关键词
Lung cancer; Guidelines; Elderly; Surgery; Survival; Treatment decision; Inequalities; CLINICAL-PRACTICE; OLDER-ADULTS; CARE; AGE; REGISTRATION; RADIOTHERAPY; COMORBIDITY; MANAGEMENT; DIAGNOSIS; TRIALS;
D O I
10.1016/j.lungcan.2022.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Mean age at diagnosis of lung cancer is increasing with increasing age in Western populations. The present study was designed to evaluate the effect of adherence to first-line treatment guidelines on overall survival (OS) in elderly patients with non-small-cell lung cancer (NSCLC) and reasons for non-adherence to treatment guidelines. Materials and methods: All patients aged >= 65 years diagnosed with NSCLC in Ostrobothnia, Finland, during the years 2016 to 2020 were identified from hospital registries. Adherence of first-line treatment to contemporary treatment guidelines was analysed based on diagnosis, tumour stage and performance status (PS), as was the effect of adherence on OS. Results: A review of hospital registries identified 238 NSCLC patients aged & GE; 65 years. Guideline adherence by stage decreased significantly with age, with 66.4% of patients aged 65 to 74 years, but only 33.3% of those aged > 80 years treated according to guidelines (p < 0.001). Other factors associated with non-adherence to guide-lines included poor PS, frailty, and limited lung function. Of the patients with PS 0-2, 26.9% were under-treated according to guidelines. Reasons for under-treatment included comorbidities, decreased lung function, physician decision to reduce treatment intensity or recommend best supportive care, patient choice and PS decline before treatment initiation. Guideline adherence increased overall OS of elderly NSCLC patients in all stages. Elderly PS 2 patients appear to benefit from guideline adherence and active treatment. In contrast, active treatment did not benefit patients with PS 3-4. Conclusions: Guideline adherence was associated with increased OS in elderly NSCLC patients. Almost 10% of elderly and otherwise fit NSCLC patients were not treated according to guidelines and could have benefitted from more intensive treatment.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [31] Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer
    Janssen-Heijnen, Maryska L. G.
    Maas, Huub A. A. M.
    Koning, Caro C. E.
    van der Bruggen-Bogaarts, Brigitte A. H. A.
    Groen, Harry J. M.
    Wymenga, A. N. Machteld
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 71 - 77
  • [32] Are TKIs favourable for the elderly with non-small-cell lung cancer?
    Rossi, Sabrina
    D'Argento, Ettore
    Schinzari, Giovanni
    Dadduzio, Vincenzo
    Di Noia, Vincenzo
    Cassano, Alessandra
    Barone, Carlo
    ONCOTARGET, 2016, 7 (30) : 46871 - 46877
  • [33] The effect of lymph node ratio on survival in non-small-cell lung cancer
    Sezen, Celal Bugra
    Kalafat, Cem Emrah
    Dogru, Mustafa Vedat
    Aker, Cemal
    Erdogu, Volkan
    Saydam, Ozkan
    Metin, Muzaffer
    ACTA CHIRURGICA BELGICA, 2023, 123 (01) : 36 - 42
  • [34] Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers
    Xie, Dong
    Allen, Mark S.
    Marks, Randolph
    Jiang, Gening
    Sun, Zhifu
    Nichols, Frances
    Zhang, Mingrui
    Chen, Chang
    Aubry, Marie-Christine
    Jatoi, Aminah
    Garces, Yolanda I.
    Mansfield, Aaron
    Wigle, Dennis
    Molina, Julian
    Deschamps, Claude
    Yang, Ping
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 53 (06) : 1214 - 1222
  • [35] Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients &gt;80
    Janssen-Heijnen, M. L. G.
    Maas, H. A. A. M.
    Siesling, S.
    Koning, C. C. E.
    Coebergh, J. W. W.
    Groen, H. J. M.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 954 - 960
  • [36] Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
    Zaborowska-Szmit, Magdalena
    Olszyna-Serementa, Marta
    Kowalski, Dariusz M.
    Szmit, Sebastian
    Krzakowski, Maciej
    CANCERS, 2021, 13 (18)
  • [37] Impact of time-to-treatment on overall survival of non-small cell lung cancer patients - an analysis of the national cancer database
    Anggondowati, Trisari
    Ganti, Apar Kishor
    Islam, K. M. Monirul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1202 - 1211
  • [38] Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy
    Guerin, A.
    Sasane, M.
    Wakelee, H.
    Zhang, J.
    Culver, K.
    Dea, K.
    Nitulescu, R.
    Galebach, P.
    Macalalad, A. R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (08) : 1587 - 1597
  • [39] Surgical treatment of non-small-cell lung cancer
    Schuhan, C.
    Dienemann, H.
    ONKOLOGE, 2011, 17 (08): : 684 - +
  • [40] Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer
    Nishimyo, Keiko
    Ikeda, Shunya
    Fushimi, Kiyohide
    Yamazaki, Tsutomu
    Ishikawa, Koichi B.
    FUTURE ONCOLOGY, 2025, : 1101 - 1111